Checkpoint Inhibitor denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Checkpoint Inhibitor — Experimental / Investigational

UHC's "experimental or investigational" denial classification is one of the most contested in oncology. UHC applies this label when it determines that the evidence base for a particular use does not yet meet its internal standard for "proven" or "established" medical practice. This happens most often with: off-label uses of FDA-approved checkpoint inhibitors; newer approvals not yet reflected in UHC's coverage policy; and combination or sequencing strategies where the evidence is emerging but has guideline support.

Critically, an "experimental" determination by the insurer is not the same as an FDA finding. An FDA-approved checkpoint inhibitor cannot legally be called experimental for its approved indication — and for off-label oncology uses, federal law and most state laws require coverage of compendia-supported uses regardless of insurer classification.

## Federal Appeal Framework

• Internal appeal: File within 180 days; expedited track (72-hour decision) applies when delay poses serious health risk.
• ACA §2719 external review: This is often the strongest lever for experimental denials — an independent review organization applies "generally accepted standards of medical practice," which is a broader standard than UHC's internal coverage policy. File for external review within the ~4-month window.
• ERISA §503 (employer plans): Request the full administrative file, including the clinical evidence review UHC conducted and the specific policy definition of "experimental" applied.
• State protections: Many states require coverage of clinical trials and compendia-supported oncology uses; confirm whether state law or ERISA governs your plan.

## Documentation to Gather

1. FDA approval status: Confirm and document the FDA approval status of the specific checkpoint inhibitor for the relevant indication — from the FDA label or FDA.gov. 2. Compendia listing: Ask the oncologist to identify the NCCN, Micromedex, or DrugDex entry supporting the use; this is the primary statutory basis for coverage of off-label oncology drugs. 3. Prescriber letter on evidence base: The oncologist should summarize the clinical evidence supporting the use, reference the applicable guideline category, and explain why the treatment meets the standard of care for this patient. 4. UHC's coverage policy: Obtain the specific coverage determination policy UHC applied and identify where the patient's case fits or diverges from it. 5. Peer-reviewed literature: Your oncologist can attach key published studies or meta-analyses supporting the use — the external reviewer will consider this.

## Criteria-Mapping Structure

Challenge the "experimental" label head-on: first, confirm whether the use is FDA-approved (in which case UHC cannot apply this label for the approved indication); second, if off-label, cite the compendia listing and applicable guideline; third, address UHC's specific coverage criteria point by point with clinical evidence. The external review process is particularly effective here because the IRO standard — generally accepted medical practice — tends to align more closely with oncology guidelines than insurer internal policies do.